Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D1DI
|
|||
| Former ID |
DAP000943
|
|||
| Drug Name |
Arformoterol
|
|||
| Synonyms |
67346-49-0; Brovana; UNII-F91H02EBWT; Arformoterol tartrate; CHEMBL1363; F91H02EBWT; CHEBI:408174; Brovana (TN); Formoterol/fluticasone propionate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Approved | [1], [2] | |
| Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 4 | [3] | ||
| Therapeutic Class |
Bronchodilator Agents
|
|||
| Company |
Sepracor phamaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H24N2O4
|
|||
| Canonical SMILES |
CC(CC1=CC=C(C=C1)OC)NCC(C2=CC(=C(C=C2)O)NC=O)O
|
|||
| InChI |
1S/C19H24N2O4/c1-13(9-14-3-6-16(25-2)7-4-14)20-11-19(24)15-5-8-18(23)17(10-15)21-12-22/h3-8,10,12-13,19-20,23-24H,9,11H2,1-2H3,(H,21,22)/t13-,19+/m1/s1
|
|||
| InChIKey |
BPZSYCZIITTYBL-YJYMSZOUSA-N
|
|||
| CAS Number |
CAS 67346-49-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979300, 9471432, 14827391, 14900508, 36413919, 46506392, 48416036, 50940892, 51091794, 57355509, 85599207, 103450411, 104039882, 111687869, 126685257, 135230453, 136046712, 137001399, 142226212, 152109087, 160964600, 162201740, 163414832, 163686492, 175266951, 175269513, 179150479, 185998767, 187051782, 210281489, 223553207, 223678424, 224468537, 226396278, 241132564, 252425627
|
|||
| ChEBI ID |
CHEBI:408174
|
|||
| ADReCS Drug ID | BADD_D00159 ; BADD_D00160 | |||
| SuperDrug ATC ID |
R03AC13
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor beta-2 (ADRB2) | Target Info | Agonist | [4], [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| cGMP-PKG signaling pathway | ||||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Endocytosis | ||||
| Adrenergic signaling in cardiomyocytes | ||||
| Salivary secretion | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Beta2 adrenergic receptor signaling pathway | ||||
| Pathway Interaction Database | Arf6 trafficking events | |||
| Arf6 signaling events | ||||
| Reactome | Adrenoceptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Vitamin D Receptor Pathway | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7479). | |||
| REF 2 | Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91. | |||
| REF 3 | ClinicalTrials.gov (NCT02491970) Study to Evaluate Small Airway Parameters of Fluticasone/Formoterol (Flutiform) Compared to Fluticasone/Salmeterol in Asthma Patients. | |||
| REF 4 | Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9. | |||
| REF 5 | Arformoterol: (R,R)-eformoterol, (R,R)-formoterol, arformoterol tartrate, eformoterol-sepracor, formoterol-sepracor, R,R-eformoterol, R,R-formoterol. Drugs R D. 2004;5(1):25-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.